This study retrospectively analyzed the clinical data of ROP children treated with intravitreal anti-VEGF therapy, explored the risk factors for ROP reactivate, and constructed a nomogram model to predict the risk of ROP reactivate, providing a basis for early prediction and intervention of ROP reactivate. The gene discussed is VEGFA; the disease is retinopathy of prematurity.